Feature

Annual statements would help advisers to sell more protection. Adam Higgs reveals how.

Munich Re research has found non‑disclosure to be a lot more common than previously thought. As Lee Lovett explains, stopping it is not easy.

One of the most exciting medical advancements in recent times is Nanomedicine, the development of microscopic particles with healing effects. Dr Ulrike Sucher offers a health insurer's perspective.

As technology becomes increasingly important, Owain Thomas examines how platforms can support the employee benefits.

Company cash plans have experienced the most growth in recent years. But do issues around excess and how employers integrate these with traditional PMI policies mean they are heading for trouble? Fiona Murphy reports

Did a commission ban in the Netherlands damage the market? Rijn van der Linden says not and draws some parallels with the UK

Prostate cancer is often in the media spotlight, but the recent news has been positive. Fergus Bescoby explains.

"I am a generalist IFA. How can I justify to my clients that protection products are still based on commission payments? A few of them have heard that most advisers now charge fees for financial advice and find it hard to get their head round the difference...

CIExpert is frequently asked why the PruProtect plan is not included within the comparison section of the site. Alan Lakey explains.

LV='s Mark Jones goes through the typical reasons clients may be resistant to taking out insurance and how advisers can address these.